In vitro studies based on HER2+ breast cancer cell lines with either intrinsic or acquired resistance to trastuzumab, lapatinib or both trastuzumab and lapatinib have been performed to determine the role of ERα in the onset of resistance to HER2-targeted therapies [15]. This evidence concerns the gene ERBB2 and breast cancer.